Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for ventricular rate control in non-paroxysmal atrial fibrillation
IRCT20191230045950N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Ivabradine with Placebo (2 arms). Primary endpoints: Mean 24-hour ventricular rate, Mean daytime ventricular rate and 1 more. Started Feb 2022; status: completed.
02
Drugs
ivabradine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20191230045950N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191230045950N2.